9.66%QQQQ 30.60 8.96%XLF 15.45 10.85%
Digg
Del.icio.us
Newsvine 
Facebook
Stumbleupon
NEW YORK - Diversified health care products company Johnson & Johnson said Friday it will receive $200 million from biotechnology company Amgen Inc. as part of a settlement of an antitrust lawsuit.
In the lawsuit, J&J's Ortho Biotech unit alleged that Amgen violated antitrust laws when it gave discounts to oncology clinics on its products. Those products included Aranesp, which treats anemia associated with chemotherapy treatment, along with Neupogen and Neulasta, which prevent infections in chemotherapy patients.
J&J makes Epogen, which treats anemia associated with chemotherapy treatment. The company expects to include the settlement with its third-quarter results.
The lawsuit in New Jersey District Court will be dismissed.
In a statement, Amgen said it continues to deny that its challenged conduct was unlawful, and admits to no wrongdoing in the settlement.
Shares of New Brunswick, N.J.-based Johnson & Johnson fell 68 cents to close at $66.26 while shares of Thousand Oaks, Calif.-based Amgen fell 67 cents to close at $51.02.
Republican John McCain and Democrat Barack Obama are heading into the final pres...
Joey Chestnut set a new fast-eating record when he ate 45 pizza slices in 10 min...
Oil prices rebounded from a 13-month low to rise above $81 a barrel Monday in As...
Get your next web design project done with our los angeles web design team - Best web design with great price.
|
Partners   
|
© 2008 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives
EMAIL
PRINT
RSS
SHARE
